Search

Your search keyword '"Bouabdallah, Reda"' showing total 864 results
Start Over Author "Bouabdallah, Reda"
864 results on '"Bouabdallah, Reda"'

1. Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life—experience of the French Network

Author

Schenone, Laurence, Houillier, Caroline, Tanguy, Marie Laure, Choquet, Sylvain, Agbetiafa, Kossi, Ghesquières, Hervé, Damaj, Gandhi, Schmitt, Anna, Bouabdallah, Krimo, Ahle, Guido, Gressin, Remy, Cornillon, Jérôme, Houot, Roch, Marolleau, Jean-Pierre, Fornecker, Luc-Matthieu, Chinot, Olivier, Peyrade, Frédéric, Bouabdallah, Reda, Moluçon-Chabrot, Cécile, Gyan, Emmanuel, Chauchet, Adrien, Casasnovas, Olivier, Oberic, Lucie, Delwail, Vincent, Abraham, Julie, Roland, Virginie, Waultier-Rascalou, Agathe, Willems, Lise, Morschhauser, Franck, Fabbro, Michel, Ursu, Renata, Thieblemont, Catherine, Jardin, Fabrice, Tempescul, Adrian, Malaise, Denis, Touitou, Valérie, Nichelli, Lucia, Le Garff-Tavernier, Magali, Plessier, Aurélie, Bourget, Philippe, Bonmati, Caroline, Wantz-Mézières, Sophie, Giordan, Quentin, Dorvaux, Véronique, Charron, Cyril, Jabeur, Waliyde, Hoang-Xuan, Khê, Taillandier, Luc, and Soussain, Carole

Published
2022
Full Text
View/download PDF

2. Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study

Author

Bachy, Emmanuel, Houot, Roch, Feugier, Pierre, Bouabdallah, Krimo, Bouabdallah, Reda, Virelizier, Emmanuelle Nicolas, Maerevoet, Marie, Fruchart, Christophe, Snauwaert, Sylvia, Le Gouill, Steven, Marolleau, Jean-Pierre, Molina, Lysiane, Moluçon-Chabrot, Cécile, Thieblemont, Catherine, Tilly, Hervé, Bijou, Fontanet, Haioun, Corinne, Van den Neste, Eric, Fabiani, Bettina, Meignan, Michel, Cartron, Guillaume, Salles, Gilles, Casasnovas, Olivier, and Morschhauser, Franck

Published
2022
Full Text
View/download PDF

3. Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma

Author

Lemonnier, François, Safar, Violaine, Beldi-Ferchiou, Asma, Cottereau, Anne-Ségolène, Bachy, Emmanuel, Cartron, Guillaume, Fataccioli, Virginie, Pelletier, Laura, Robe, Cyrielle, Letourneau, Audrey, Missiaglia, Edoardo, Fourati, Slim, Moles-Moreau, Marie-Pierre, Delmer, Alain, Bouabdallah, Reda, Voillat, Laurent, Becker, Stéphanie, Bossard, Céline, Parrens, Marie, Casasnovas, Olivier, Cacheux, Victoria, Régny, Caroline, Camus, Vincent, Delfau-Larue, Marie-Hélène, Meignan, Michel, de Leval, Laurence, Gaulard, Philippe, and Haioun, Corinne

Published
2021
Full Text
View/download PDF

4. Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome

Author

Castagna, Luca, Pagliardini, Thomas, Bramanti, Stefania, Schiano de Colella, Jean Marc, Montes de Oca, Catalina, Bouabdallah, Reda, Mariotti, Jacopo, Fürst, Sabine, Granata, Angela, De Philippis, Chiara, Harbi, Samia, Sarina, Barbara, Legrand, Faezeh, Maisano, Valerio, Weiller, Pierre Jean, Chabannon, Christian, Carlo-Stella, Carmelo, Santoro, Armando, Blaise, Didier, and Devillier, Raynier

Published
2021
Full Text
View/download PDF

5. ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells

Author

Amatore, Florent, Ortonne, Nicolas, Lopez, Marc, Orlanducci, Florence, Castellano, Rémy, Ingen-Housz-Oro, Saskia, De Croos, Amandine, Salvado, Clémentine, Gorvel, Laurent, Goubard, Armelle, Collette, Yves, Bouabdallah, Réda, Schiano, Jean-Marc, Bonnet, Nathalie, Grob, Jean-Jacques, Gaulard, Philippe, Bagot, Martine, Bensussan, Armand, Berbis, Philippe, and Olive, Daniel

Published
2020
Full Text
View/download PDF

6. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study

Author

Michot, Jean-Marie, Bouabdallah, Reda, Vitolo, Umberto, Doorduijn, Jeanette K, Salles, Gilles, Chiappella, Annalisa, Zinzani, Pier Luigi, Bijou, Fontanet, Kersten, Marie José, Sarmiento, Rafael, Mosulen, Silvia, Mendez, Cristina, Uttamsingh, Shailaja, Pourdehnad, Michael, Hege, Kristen, Chen, Tianlei, Klein, Christian, Hagner, Patrick R, Nikolova, Zariana, and Ribrag, Vincent

Published
2020
Full Text
View/download PDF

7. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

Author

Kalakonda, Nagesh, Maerevoet, Marie, Cavallo, Federica, Follows, George, Goy, Andre, Vermaat, Joost S P, Casasnovas, Olivier, Hamad, Nada, Zijlstra, Josée M, Bakhshi, Sameer, Bouabdallah, Reda, Choquet, Sylvain, Gurion, Ronit, Hill, Brian, Jaeger, Ulrich, Sancho, Juan Manuel, Schuster, Michael, Thieblemont, Catherine, De la Cruz, Fátima, Egyed, Miklos, Mishra, Sourav, Offner, Fritz, Vassilakopoulos, Theodoros P, Warzocha, Krzysztof, McCarthy, Daniel, Ma, Xiwen, Corona, Kelly, Saint-Martin, Jean-Richard, Chang, Hua, Landesman, Yosef, Joshi, Anita, Wang, Hongwei, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Van Den Neste, Eric, and Canales, Miguel A

Published
2020
Full Text
View/download PDF

9. Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers

Author

Hueso, Thomas, Gastinne, Thomas, Garciaz, Sylvain, Tchernonog, Emmanuelle, Delette, Caroline, Casasnovas, René-Olivier, Durot, Eric, Houot, Roch, Tessoulin, Benoît, Tournilhac, Olivier, Malak, Sandra, Gyan, Emmanuel, Fornecker, Luc-Matthieu, Abraham, Julie, Delapierre, Baptiste, Peyrade, Frédéric, Lemal, Richard, Gressin, Rémy, Chantepie, Sylvain, Borel, Cécile, Morello, Rémy, Bouabdallah, Krimo, Ibrahim, Ahmad, Bouabdallah, Reda, Le Gouill, Steven, and Damaj, Gandhi

Published
2020
Full Text
View/download PDF

11. Peripheral Blood Stem Cells versus Bone Marrow for T Cell–Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide in Hodgkin Lymphoma

Author

Mariotti, Jacopo, Devillier, Raynier, Bramanti, Stefania, Giordano, Laura, Sarina, Barbara, Furst, Sabine, Granata, Angela, Maisano, Valerio, Pagliardini, Thomas, De Philippis, Chiara, Kogan, Maria, Faucher, Catherine, Harbi, Samia, Chabannon, Christian, Carlo-Stella, Carmelo, Bouabdallah, Reda, Santoro, Armando, Blaise, Didier, and Castagna, Luca

Published
2019
Full Text
View/download PDF

12. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study

Author

Morschhauser, Franck, Le Gouill, Steven, Feugier, Pierre, Bailly, Sarah, Nicolas-Virelizier, Emmanuelle, Bijou, Fontanet, Salles, Gilles A, Tilly, Hervé, Fruchart, Christophe, Van Eygen, Koen, Snauwaert, Sylvia, Bonnet, Christophe, Haioun, Corinne, Thieblemont, Catherine, Bouabdallah, Reda, Wu, Ka Lung, Canioni, Danielle, Meignin, Véronique, Cartron, Guillaume, and Houot, Roch

Published
2019
Full Text
View/download PDF

13. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study

Author

Tilly, Hervé, Morschhauser, Franck, Casasnovas, Olivier, Molina, Thierry Jo, Feugier, Pierre, Gouill, Steven Le, Haioun, Corinne, Tournilhac, Olivier, Bouabdallah, Reda, Gabarre, Jean, Lamy, Thierry, Cabeçadas, José, Becker, Stéphanie, Jardin, Fabrice, Mounier, Nicolas, and Salles, Gilles

Published
2018
Full Text
View/download PDF

14. A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type

Author

Beylot-Barry, Marie, Mermin, Diane, Maillard, Aline, Bouabdallah, Reda, Bonnet, Nathalie, Duval-Modeste, Anne-Bénédicte, Mortier, Laurent, Ingen-Housz-Oro, Saskia, Ram-Wolff, Caroline, Barete, Stéphane, Dalle, Stéphane, Maubec, Eve, Quereux, Gaelle, Templier, Isabelle, Bagot, Martine, Grange, Florent, Joly, Pascal, Vergier, Béatrice, Vially, Pierre-Julien, Gros, Audrey, Pham-Ledard, Anne, Frison, Eric, and Merlio, Jean-Philippe

Published
2018
Full Text
View/download PDF

15. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy

Author

Bachy, Emmanuel, Maurer, Matthew J., Habermann, Thomas M., Gelas-Dore, Bénédicte, Maucort-Boulch, Delphine, Estell, Jane A., Van den Neste, Eric, Bouabdallah, Réda, Gyan, Emmanuel, Feldman, Andrew L., Bargay, Joan, Delmer, Alain, Slager, Susan L., Gomes da Silva, Maria, Fitoussi, Olivier, Belada, David, Maisonneuve, Hervé, Intragumtornchai, Tanin, Ansell, Stephen M., Lamy, Thierry, Dartigues, Peggy, Link, Brian K., Seymour, John F., Cerhan, James R., and Salles, Gilles

Published
2018
Full Text
View/download PDF

16. Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients

Author

Granata, Angela, Fürst, Sabine, Bramanti, Stefania, Legrand, Faezeh, Sarina, Barbara, Harbi, Samia, De Philippis, Chiara, Faucher, Catherine, Chabannon, Christian, Lemarie, Claude, Calmels, Boris, Mariotti, Jacopo, Maisano, Valerio, Weiller, Pierre-Jean, Mokart, Djamel, Vey, Norbert, Bouabdallah, Reda, Castagna, Luca, Blaise, Didier, and Devillier, Raynier

Published
2019
Full Text
View/download PDF

17. Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60 years with hematological malignancies: a single-center experience of 209 patients

Author

Pagliardini, Thomas, Harbi, Samia, Fürst, Sabine, Castagna, Luca, Legrand, Faezeh, Faucher, Catherine, Granata, Angela, Weiller, Pierre-Jean, Calmels, Boris, Lemarie, Claude, Chabannon, Christian, Bouabdallah, Reda, Mokart, Djamel, Vey, Norbert, Blaise, Didier, and Devillier, Raynier

Published
2019
Full Text
View/download PDF

18. Haploidentical related donor compared to HLA-identical donor transplantation for chemosensitive Hodgkin lymphoma patients

Author

Castagna, Luca, Busca, Alessandro, Bramanti, Stefania, Raiola Anna, Maria, Malagola, Michele, Ciceri, Fabio, Arcese, William, Vallisa, Daniele, Patriarca, Francesca, Specchia, Giorgina, Raimondi, Roberto, Devillier, Raynier, Furst, Sabine, Giordano, Laura, Sarina, Barbara, Mariotti, Jacopo, Olivieri, Attilio, Bouabdallah, Reda, Carlo-Stella, Carmelo, Rambaldi, Alessandro, Santoro, Armando, Corradini, Paolo, Bacigalupo, Andrea, Bonifazi, Francesca, and Blaise, Didier

Published
2020
Full Text
View/download PDF

19. ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)–Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial

Author

Fermé, Christophe, Thomas, José, Brice, Pauline, Casasnovas, Olivier, Vranovsky, Andrej, Bologna, Serge, Lugtenburg, Pieternella J., Bouabdallah, Réda, Carde, Patrice, Sebban, Catherine, Eghbali, Houchingue, Salles, Gilles, van Imhoff, Gustaaf W., Thyss, Antoine, Noordijk, Evert M., Reman, Oumédaly, Lybeert, Marnix L.M., Janvier, Maud, Spina, Michele, Audhuy, Bruno, Raemaekers, John M.M., Delarue, Richard, Anglaret, Bruno, de Weerdt, Okke, Marjanovic, Zora, Tersteeg, Robbert J.H.A., de Jong, Daphne, Brière, Josette, and Henry-Amar, Michel

Published
2017
Full Text
View/download PDF

20. Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients

Author

Xerri, Luc, Huet, Sarah, Venstrom, Jeffrey M., Szafer-Glusman, Edith, Fabiani, Bettina, Canioni, Danielle, Chassagne-Clément, Catherine, Dartigues-Cuilléres, Peggy, Charlotte, Fréderic, Laurent, Camille, Gelas-Dore, Benedicte, Bolen, Christopher R., Punnoose, Elizabeth, Bouabdallah, Reda, Brice, Pauline, Morschhauser, Franck, Cartron, Guillaume, Olive, Daniel, and Salles, Gilles

Published
2017
Full Text
View/download PDF

21. A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma.

Author

Noel, Robin, Zemmour, Christophe, Montes de Oca, Catalina, Belmecheri, Nawel, Aurran-Schleinitz, Thérèse, Coso, Diane, Lopez Almeida, Leonor, Mescam, Lénaïg, Vey, Norbert, Bladé, Jean Sébastien, Slama, Borhane, Bouabdallah, Reda, and Schiano de Colella, Jean-Marc

Subjects
DIFFUSE large B-cell lymphomas, B cell lymphoma, LENALIDOMIDE, PROGRESSION-free survival, RITUXIMAB
Abstract

Relapsed/Refractory Diffuse Large B Cell Lymphoma have a dismal prognosis in need of innovative treatments. This prospective phase 2 study enrolled 32 patients between 2013 and 2017 with Relapsed/Refractory Diffuse Large B Cell Lymphoma treated with Rituximab and Lenalidomide (R2). Median age was 69 years (40–86), 90.1% had received at least 2 prior lines of treatment, 81% were defined as having High Risk disease according to our criteria and ECOG performance status was > 2 in 51.6%. Patients received a median number of 2 cycles of R2 (1–12). With a median follow up of 22.6 months, the objective response rate was 12.5%. Median progression free survival was 2.6 months (95% CI, [1.7–2.9]) and median overall survival was 9.3 months (95% CI, [5.1–Not estimable]). This study therefore did not achieve its primary endpoint and the R2 regimen cannot be recommended in Relapsed/Refractory Diffuse Large B Cell Lymphoma patients with High Risk features. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

22. Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma

Author

Kroschinsky, Frank, Middeke, Jan Moritz, Janz, Martin, Lenz, Georg, Witzens-Harig, Mathias, Bouabdallah, Reda, La Rosée, Paul, Viardot, Andreas, Salles, Gilles, Kim, Seok Jin, Kim, Tae Min, Ottmann, Oliver, Chromik, Joerg, Quinson, Anne-Marie, von Wangenheim, Ute, Burkard, Ute, Berk, Andreas, and Schmitz, Norbert

Published
2021
Full Text
View/download PDF

23. Data from Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy

Author

Le, Kieu-Suong, primary, Thibult, Marie-Laure, primary, Just-Landi, Sylvain, primary, Pastor, Sonia, primary, Gondois-Rey, Françoise, primary, Granjeaud, Samuel, primary, Broussais, Florence, primary, Bouabdallah, Reda, primary, Colisson, Renaud, primary, Caux, Christophe, primary, Ménétrier-Caux, Christine, primary, Leroux, Dominique, primary, Xerri, Luc, primary, and Olive, Daniel, primary

Published
2023
Full Text
View/download PDF

24. Supplementary figures and tables from Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy

Author

Le, Kieu-Suong, primary, Thibult, Marie-Laure, primary, Just-Landi, Sylvain, primary, Pastor, Sonia, primary, Gondois-Rey, Françoise, primary, Granjeaud, Samuel, primary, Broussais, Florence, primary, Bouabdallah, Reda, primary, Colisson, Renaud, primary, Caux, Christophe, primary, Ménétrier-Caux, Christine, primary, Leroux, Dominique, primary, Xerri, Luc, primary, and Olive, Daniel, primary

Published
2023
Full Text
View/download PDF

25. Supplementary figures legends from Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy

Author

Le, Kieu-Suong, primary, Thibult, Marie-Laure, primary, Just-Landi, Sylvain, primary, Pastor, Sonia, primary, Gondois-Rey, Françoise, primary, Granjeaud, Samuel, primary, Broussais, Florence, primary, Bouabdallah, Reda, primary, Colisson, Renaud, primary, Caux, Christophe, primary, Ménétrier-Caux, Christine, primary, Leroux, Dominique, primary, Xerri, Luc, primary, and Olive, Daniel, primary

Published
2023
Full Text
View/download PDF

27. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

Author

Hermine, Olivier, Hoster, Eva, Walewski, Jan, Bosly, André, Stilgenbauer, Stephan, Thieblemont, Catherine, Szymczyk, Michal, Bouabdallah, Reda, Kneba, Michael, Hallek, Michael, Salles, Gilles, Feugier, Pierre, Ribrag, Vincent, Birkmann, Josef, Forstpointner, Roswitha, Haioun, Corinne, Hänel, Mathias, Casasnovas, René Olivier, Finke, Jürgen, Peter, Norma, Bouabdallah, Kamal, Sebban, Catherine, Fischer, Thomas, Dührsen, Ulrich, Metzner, Bernd, Maschmeyer, Georg, Kanz, Lothar, Schmidt, Christian, Delarue, Richard, Brousse, Nicole, Klapper, Wolfram, Macintyre, Elizabeth, Delfau-Larue, Marie-Hélène, Pott, Christiane, Hiddemann, Wolfgang, Unterhalt, Michael, and Dreyling, Martin

Published
2016
Full Text
View/download PDF

28. Haploidentical T Cell–Replete Transplantation with Post-Transplantation Cyclophosphamide for Patients in or above the Sixth Decade of Age Compared with Allogeneic Hematopoietic Stem Cell Transplantation from an Human Leukocyte Antigen–Matched Related or Unrelated Donor

Author

Blaise, Didier, Fürst, Sabine, Crocchiolo, Roberto, El-Cheikh, Jean, Granata, Angela, Harbi, Samia, Bouabdallah, Reda, Devillier, Raynier, Bramanti, Stephania, Lemarie, Claude, Picard, Christophe, Chabannon, Christian, Weiller, Pierre-Jean, Faucher, Catherine, Mohty, Bilal, Vey, Norbert, and Castagna, Luca

Published
2016
Full Text
View/download PDF

29. Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High-Dose Therapy with Stem Cell Transplantation in Poor-Risk Patients with Diffuse Large B Cell Lymphoma

Author

Fruchart, Christophe, Tilly, Hervé, Morschhauser, Franck, Ghesquières, Hervé, Bouteloup, Marie, Fermé, Christophe, Van Den Neste, Eric, Bordessoule, Dominique, Bouabdallah, Reda, Delmer, Alain, Casasnovas, René Olivier, Ysebaert, Loïc, Ciappuccini, Renaud, Briere, Josette, and Gisselbrecht, Christian

Published
2014
Full Text
View/download PDF

30. Autologous Stem Cell Transplant in 2nd Line DLBCL in 2022, Still the Standard of Care ? a Monocentric Experience

Author

Collignon, Aude, primary, Bouchacourt, Benjamin, additional, Sfumato, Patrick, additional, Brisou, Gabriel, additional, Schiano de Collela, Jean Marc, additional, Inchiappa, Luca, additional, Calmels, Boris, additional, Lemarié, Claude, additional, Reichert, Tibaulth, additional, Harbi, Samia, additional, Devillier, Raynier, additional, Calleja, Anne, additional, Pagliardini, Thomas, additional, Morel, Guillaume, additional, Granata, Angela, additional, Vey, Norbert, additional, Bouabdallah, Reda, additional, Blaise, Didier, additional, Chabannon, Christian, additional, Noel, Robin, additional, and Montes De Oca, Catalina, additional

Published
2022
Full Text
View/download PDF

32. Antithymocyte Globulin in Reduced-Intensity Conditioning Regimen Allows a High Disease-Free Survival Exempt of Long-Term Chronic Graft-versus-Host Disease

Author

Devillier, Raynier, Fürst, Sabine, El-Cheikh, Jean, Castagna, Luca, Harbi, Samia, Granata, Angela, Crocchiolo, Roberto, Oudin, Claire, Mohty, Bilal, Bouabdallah, Reda, Chabannon, Christian, Stoppa, Anne-Marie, Charbonnier, Aude, Broussais-Guillaumot, Florence, Calmels, Boris, Lemarie, Claude, Rey, Jèrôme, Vey, Norbert, and Blaise, Didier

Published
2014
Full Text
View/download PDF

36. Positron Emission Tomography-Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study.

Author

UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Casasnovas, René-Olivier, Bouabdallah, Reda, Brice, Pauline, Lazarovici, Julien, Ghesquieres, Hervé, Stamatoullas, Aspasia, Dupuis, Jehan, Gac, Anne-Claire, Gastinne, Thomas, Joly, Bertrand, Bouabdallah, Krimo, Nicolas-Virelizier, Emmanuelle, Feugier, Pierre, Morschhauser, Franck, Sibon, David, Bonnet, Christophe, Berriolo-Riedinger, Alina, Edeline, Véronique, Parrens, Marie, Damotte, Diane, Coso, Diane, André, Marc, Meignan, Michel, Rossi, Cédric, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'hématologie, Casasnovas, René-Olivier, Bouabdallah, Reda, Brice, Pauline, Lazarovici, Julien, Ghesquieres, Hervé, Stamatoullas, Aspasia, Dupuis, Jehan, Gac, Anne-Claire, Gastinne, Thomas, Joly, Bertrand, Bouabdallah, Krimo, Nicolas-Virelizier, Emmanuelle, Feugier, Pierre, Morschhauser, Franck, Sibon, David, Bonnet, Christophe, Berriolo-Riedinger, Alina, Edeline, Véronique, Parrens, Marie, Damotte, Diane, Coso, Diane, André, Marc, Meignan, Michel, and Rossi, Cédric

Abstract

The AHL2011 study (ClinicalTrials.gov identifier: NCT01358747) demonstrated that a positron emission tomography (PET)-driven de-escalation strategy after two cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP) provides similar progression-free survival (PFS) and overall survival (OS) and reduces early toxicity compared with a nonmonitored standard treatment. Here, we report, with a prolonged follow-up, the final study results. Patients with advanced Hodgkin lymphoma (stage III, IV, or IIB with mediastinum/thorax ratio > 0.33 or extranodal involvement) age 16-60 years were prospectively randomly assigned between 6 × BEACOPP and a PET-driven arm after 2 × BEACOPP delivering 4 × ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) in PET2- and 4 × BEACOPP in PET2+ patients. PET performed after four cycles of chemotherapy had to be negative to complete the planned treatment. In total, 823 patients were enrolled including 413 in the standard arm and 410 in the PET-driven arm. With a 67.2-month median follow-up, 5-year PFS (87.5% 86.7%; hazard ratio [HR] = 1.07; 95% CI, 0.74 to 1.57; = .67) and OS (97.7% in both arms; HR = 1.012; 95% CI, 0.50 to 2.10; = .53) were similar in both randomization arms. In the whole cohort, full interim PET assessment predicted patients' 5-year PFS (92.3% in PET2-/PET4-, 75.4% [HR = 3.26; 95% CI, 18.3 to 5.77] in PET2+/PET4- and 46.5% [HR = 12.4; 95% CI, 7.31 to 19.51] in PET4+ patients, respectively; < .0001) independent of international prognosis score. Five-year OS was also affected by interim PET results, and PET2+/PET4- patients (93.5%; HR = 3.3; 95% CI, 1.07 to 10.1; = .036) and PET4+ patients (91.9%; HR = 3.756; 95% CI, 1.07 to 13.18; = .038) had a significant lower OS than PET2-/PET4- patients (98.2%). Twenty-two patients (2.7%) developed a second primary malignancy, 13 (3.2%) and 9 (2.2%) in the standard and experimental arms, respectively. The extended follow-up co

Published
2022

37. Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study.

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service de gastro-entérologie, UCL - (SLuc) Unité d'oncologie médicale, Bachy, Emmanuel, Houot, Roch, Feugier, Pierre, Bouabdallah, Krimo, Bouabdallah, Reda, Virelizier, Emmanuelle Nicolas, Maerevoet, Marie, Fruchart, Christophe, Snauwaert, Sylvia, Le Gouill, Steven, Marolleau, Jean-Pierre, Molina, Lysiane, Moluçon-Chabrot, Cécile, Thieblemont, Catherine, Tilly, Hervé, Bijou, Fontanet, Haioun, Corinne, Van den Neste, Eric, Fabiani, Bettina, Meignan, Michel, Cartron, Guillaume, Salles, Gilles, Casasnovas, Olivier, Morschhauser, Franck, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Service de gastro-entérologie, UCL - (SLuc) Unité d'oncologie médicale, Bachy, Emmanuel, Houot, Roch, Feugier, Pierre, Bouabdallah, Krimo, Bouabdallah, Reda, Virelizier, Emmanuelle Nicolas, Maerevoet, Marie, Fruchart, Christophe, Snauwaert, Sylvia, Le Gouill, Steven, Marolleau, Jean-Pierre, Molina, Lysiane, Moluçon-Chabrot, Cécile, Thieblemont, Catherine, Tilly, Hervé, Bijou, Fontanet, Haioun, Corinne, Van den Neste, Eric, Fabiani, Bettina, Meignan, Michel, Cartron, Guillaume, Salles, Gilles, Casasnovas, Olivier, and Morschhauser, Franck

Abstract

Obinutuzumab and lenalidomide (referred to as the GALEN combination) is an active immunomodulatory combination with a manageable safety profile in multiple types of lymphoma. We report efficacy and safety results for the phase 2 GALEN study in previously untreated patients with advanced follicular lymphoma (FL). Eligible patients aged ≥18 years had an Eastern Cooperative Oncology Group performance status ≤2 and high-tumor burden, grade 1 to 3a FL. Induction treatment was obinutuzumab (1000 mg IV, days 8, 15, and 22, cycle 1; day 1, cycles 2-6) plus lenalidomide (20 mg/d, days 1-21, cycle 1; days 2-22, cycles 2-6) for six 28-day cycles. Maintenance included obinutuzumab (1000 mg every 2 cycles) plus lenalidomide (10 mg, days 2-22) for ≤12 cycles (year 1) followed by obinutuzumab (1000 mg every 56 days) for 6 cycles (year 2). The primary end point was complete response rate (CRR) after induction per the 1999 International Working Group criteria. From October 2015 to February 2017, a total of 100 patients were enrolled. CRR after induction was 47%, and the overall response rate (ORR) was 92%. Post hoc analyses per the 2014 Lugano classification, including patients with missing bone marrow assessments, identified an additional 13 patients fulfilling CRR criteria, resulting in a complete metabolic response of 80% and an ORR of 94%. At a median follow-up of 3.7 years, 3-year progression-free survival and overall survival were 82% and 94%, respectively. The most common adverse event was neutropenia (48% any grade; 47% grade ≥3). Only 2% of patients presented with febrile neutropenia; others were mainly grade ≤2. No other specific grade ≥3 toxicity occurred at a frequency >3%. Overall, these results showed promising clinical efficacy for the chemotherapy-free GALEN backbone in previously untreated patients with high tumor burden FL. Except for neutropenia, the safety profile of the combination is remarkable. The study was registered at clinicaltrials.gov as #NCT01582776.

Published
2022

38. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms

Author

Ghesquières, Hervé, Cartron, Guillaume, Seymour, John Francis, Delfau-Larue, Marie-Hélène, Offner, Fritz, Soubeyran, Pierre, Perrot, Aurore, Brice, Pauline, Bouabdallah, Réda, Sonet, Anne, Dupuis, Jehan, Casasnovas, Olivier, Catalano, John Vincent, Delmer, Alain, Jardin, Fabrice, Verney, Aurélie, Dartigues, Peggy, and Salles, Gilles

Published
2012
Full Text
View/download PDF

39. Positron Emission Tomography–Driven Strategy in Advanced Hodgkin Lymphoma: Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study

Author

Casasnovas, René-Olivier, primary, Bouabdallah, Reda, additional, Brice, Pauline, additional, Lazarovici, Julien, additional, Ghesquieres, Hervé, additional, Stamatoullas, Aspasia, additional, Dupuis, Jehan, additional, Gac, Anne-Claire, additional, Gastinne, Thomas, additional, Joly, Bertrand, additional, Bouabdallah, Krimo, additional, Nicolas-Virelizier, Emmanuelle, additional, Feugier, Pierre, additional, Morschhauser, Franck, additional, Sibon, David, additional, Bonnet, Christophe, additional, Berriolo-Riedinger, Alina, additional, Edeline, Véronique, additional, Parrens, Marie, additional, Damotte, Diane, additional, Coso, Diane, additional, André, Marc, additional, Meignan, Michel, additional, and Rossi, Cédric, additional

Published
2022
Full Text
View/download PDF

41. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Author

Salles, Gilles, Seymour, John Francis, Offner, Fritz, López-Guillermo, Armando, Belada, David, Xerri, Luc, Feugier, Pierre, Bouabdallah, Réda, Catalano, John Vincent, Brice, Pauline, Caballero, Dolores, Haioun, Corinne, Pedersen, Lars Moller, Delmer, Alain, Simpson, David, Leppa, Sirpa, Soubeyran, Pierre, Hagenbeek, Anton, Casasnovas, Olivier, Intragumtornchai, Tanin, Fermé, Christophe, da Silva, Maria Gomes, Sebban, Catherine, Lister, Andrew, Estell, Jane A, Milone, Gustavo, Sonet, Anne, Mendila, Myriam, Coiffier, Bertrand, and Tilly, Hervé

Published
2011
Full Text
View/download PDF

42. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC

Author

Touzeau, Cyrille, Leux, Christophe, Bouabdallah, Reda, Roussel, Murielle, Delarue, Richard, Bouabdallah, Krimo, Thieblemont, Catherine, Cacheux, Victoria, Cartron, Guillaume, Compain, Laetitia, Gyan, Emmanuel, Morschhauser, Franck, Casasnovas, Olivier, Moles, Marie-Pierre, Michallet, Anne-Sophie, Gressin, Remy, Damaj, Gandhi, Rose, Christian, Sirvent, Anne, Hermine, Olivier, Mohty, Mohamad, Milpied, Noel, and Le Gouill, Steven

Published
2014
Full Text
View/download PDF

43. Total Metabolic Tumor Volume and Tumor Dissemination Are Independent Prognostic Factors in Advanced Hodgkin Lymphoma

Author

Kanoun, Salim, primary, Berriolo-Riedinger, Alina, additional, Cottereau, Anne Ségolène, additional, Edeline, Veronique, additional, Tal, Ilan, additional, Brice, Pauline, additional, Bouabdallah, Reda, additional, Ghesquieres, Herve, additional, Stamatoullas-Bastard, Aspasia, additional, Dupuis, Jehan, additional, André, Marc, additional, Gastinne, Thomas, additional, Lazarovici, Julien, additional, Griolet, Samuel, additional, Rossi, Cedric, additional, Meignan, Michel, additional, and Casasnovas, Rene-Olivier, additional

Published
2021
Full Text
View/download PDF

44. ICOS Is Widely Expressed in Cutaneous T-Cell Lymphoma and Its Targeting Promotes Potent Killing of Malignant Cells

Author

Amatore, Florent, primary, Ortonne, Nicolas, additional, Lopez, Marc, additional, Barré, Mathilde, additional, Orlanducci, Florence, additional, Castellano, Remy, additional, Ingen-Housz-Oro, Saskia, additional, De Croos, Amandine, additional, Gorvel, Laurent, additional, Goubard, Armelle, additional, Bouabdallah, Reda, additional, Schiano De Colella, Jean Marc, additional, Grob, Jean-Jacques, additional, Gaulard, Philippe, additional, Bagot, Martine, additional, Bensussan, Armand, additional, Delaporte, Emmanuel, additional, and Olive, Daniel, additional

Published
2021
Full Text
View/download PDF

47. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome

Author

Chetaille, Bruno, Bertucci, François, Finetti, Pascal, Esterni, Benjamin, Stamatoullas, Aspasia, Picquenot, Jean Michel, Copin, Marie Christine, Morschhauser, Frank, Casasnovas, Olivier, Petrella, Tony, Molina, Thierry, Vekhoff, Anne, Feugier, Pierre, Bouabdallah, Reda, Birnbaum, Daniel, Olive, Daniel, and Xerri, Luc

Published
2009
Full Text
View/download PDF

49. Obinutuzumab versus Rituximab in young patients with advanced DLBCL, a PET-guided and randomized phase 3 study by LYSA

Author

Le Gouill, Steven, Ghesquieres, Hervé, Obéric, Lucie, Morschhauser, Franck, Tilly, Herve, Ribrag, Vincent, Lamy, Thierry, Thieblemont, Catherine, Maisonneuve, Herve Gerard, Gressin, Remy, Bouabdallah, Krimo, Haioun, Corinne, Damaj, Gandhi, Fornecker, Luc-Matthieu, Bouabdallah, Reda, Feugier, Pierre, Sibon, David, Cartron, Guillaume, Bonnet, Christophe, André, Marc, Chartier, Loic, Ruminy, Philippe, Kraeber-Bodere, F, Bodet-Milin, C, Berriolo-Riedinger, Alina, Briere, Josette, Jais, Jean-Philippe, Molina, Thierry, Itti, Emmanuel, Casasnovas, Olivier, Centre hospitalier universitaire de Nantes (CHU Nantes), Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma (CRCINA-ÉQUIPE 10), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Institut Gustave Roussy (IGR), Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse (AMMICa), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Microenvironment, Cell Differentiation, Immunology and Cancer (MICMAC), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Pontchaillou [Rennes], Service d'Hémato-oncologie [CHU Saint-Louis], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Hôpital Michallon, CHU Pessac, CHI Créteil, Institut d'Hématologie de Basse-Normandie (IHBN), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-UNICANCER, Les Hôpitaux Universitaires de Strasbourg (HUS), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire de Liège (CHU-Liège), CHU UCL Namur, The Lymphoma Academic Research Organisation [Lyon] (LYSARC), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, Hopital Saint-Louis [AP-HP] (AP-HP), Université Paris Descartes - Paris 5 (UPD5), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon, Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Jonchère, Laurent, UCL - (MGD) Service d'hématologie, and UCL - SSS/IREC/MONT - Pôle Mont Godinne

Subjects
[SDV] Life Sciences [q-bio], [SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, [SDV]Life Sciences [q-bio], [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology
Abstract

International audience; Rituximab plus polychemotherapy is the standard of care in diffuse large B-cell lymphoma (DLBCL). GAINED, a randomized phase 3 trial, compared obinutuzumab to rituximab. Transplant-eligible patients (18-60 years) with an untreated age-adjusted International Prognostic Index (aaIPI) score ≥1 DLBCL were randomized (1:1) between obinutuzumab or rituximab and stratified by aaIPI (1; 2-3) and chemotherapy regimen (doxorubicin, cyclophosphamide, prednisone plus vindesine, bleomycin [ACVBP] or vincristine [CHOP]). Consolidation treatment was determined according to response to interim positron emission tomography (PET). Responders after cycle 2 and 4 (PET2-/PET4-) received immunochemotherapy. Responders after only cycle 4 (PET2+/4-) received transplantation. The primary objective was an 8% improvement (hazard ratio [HR] = 0.73; 80% power; α risk, 2.5%; 1-sided) in 2-year event-free survival (EFS) in the obinutuzumab arm. From September 2012, 670 patients were enrolled (obinutuzumab, n = 336; rituximab, n = 334). A total of 383 (57.2%) were aaIPI 2-3, 339 (50.6%) received CHOP. Median follow-up was 38.7 months. The 2-year EFS was similar in both groups (59.8% vs 56.6%; P = .123; HR = 0.88). The 2-year PFS in the whole cohort was 83.1% (95% confidence interval, 80% to 85.8%). PET2-/4- and PET2+/4- had similar 2-year progression-free survival (PFS) and overall survival (OS): 89.9% vs 83.9% and 94.8% vs 92.8%. The 2-year PFS and OS for PET4+ patients were 62% and 83.1%. Grade 3-5 infections were more frequent in the obinutuzumab arm (21% vs 12%). Obinutuzumab is not superior to rituximab in aaIPI ≥1 DLBCL transplant-eligible patients. This trial was registered at www.clinicaltrials.gov as #NCT01659099.

Published
2021

50. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma.

Author

UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Daniele, Patrick, Tomaras, Dimitrios, Tremblay, Gabriel, Casasnovas, Rene-Olivier, Maerevoet, Marie, Zijlstra, Josee, Follows, George, P Vermaat, Joost S, Kalakonda, Nagesh, Goy, Andre Henri, Choquet, Sylvain, Van Den Neste, Eric, Hill, Brian T, Thieblemont, Catherine, Cavallo, Federica, la Cruz, Fátima de, Kuruvilla, John, Hamad, Nada, Bouabdallah, Reda, Jäger, Ulrich, Caimi, Paolo, Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan Manuel, Schuster, Michael, Egyed, Miklós, Offner, Fritz, Vasilakopoulos, Theodoros P, Samal, Priyanka, Nagy, Agnes, Ku, Matthew, Canales Albendea, Miguel Ángel, UCL - SSS/DDUV - Institut de Duve, UCL - SSS/DDUV/BCHM - Biochimie-Recherche métabolique, UCL - (SLuc) Service d'hématologie, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Daniele, Patrick, Tomaras, Dimitrios, Tremblay, Gabriel, Casasnovas, Rene-Olivier, Maerevoet, Marie, Zijlstra, Josee, Follows, George, P Vermaat, Joost S, Kalakonda, Nagesh, Goy, Andre Henri, Choquet, Sylvain, Van Den Neste, Eric, Hill, Brian T, Thieblemont, Catherine, Cavallo, Federica, la Cruz, Fátima de, Kuruvilla, John, Hamad, Nada, Bouabdallah, Reda, Jäger, Ulrich, Caimi, Paolo, Gurion, Ronit, Warzocha, Krzysztof, Bakhshi, Sameer, Sancho, Juan Manuel, Schuster, Michael, Egyed, Miklós, Offner, Fritz, Vasilakopoulos, Theodoros P, Samal, Priyanka, Nagy, Agnes, Ku, Matthew, and Canales Albendea, Miguel Ángel

Abstract

AIM: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. PATIENTS & METHODS: Functional Assessment of Cancer Therapy (FACT) - Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. RESULTS: Treatment responders maintained higher FACT - Lymphoma (p ≤ 0.05), FACT - General (p < 0.05) and EuroQoL five-dimensions five-levels index scores (p < 0.001) beginning in cycle 3. The estimated difference in health state utilities for treatment response and progressive disease was both statistically significant and clinically meaningful (mean difference: 0.07; p = 0.001). CONCLUSION: In patients with relapsed/refractory diffuse large B-cell lymphoma, objective response to selinexor was associated with HRQoL maintenance, reduction in disease-related HRQoL decrements and higher health utilities.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results